GPR40 agonists
US12264171B2 · kind B2 · utility
0Cited by
9References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 16, 2022 |
| Grant date | Apr 1, 2025 |
| Priority date | — |
| Expiry date | May 16, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.